A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants with Sickle Cell Disease to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability, pH and Food Effect, and Preliminary Efficacy of BMS-986470

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510283-12-00

Acronym

CA230-1019

Enrollment

Registered

2025-05-16

Start date

2025-06-12

Completion date

Unknown

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Brief summary

Incidence of adverse events (AEs), serious adverse events (SAEs), AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death.

Detailed description

A summary of the exposure levels of the study drug as well as changes in levels of different types of hemoglobin including fetal and sickle forms of hemoglobin., The study will also check whether other markers connected to sickle cell disease are improving

Interventions

DRUGN/A

DRUGBMS-986470

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events (AEs), serious adverse events (SAEs), AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death.	—

Secondary

Measure	Time frame
A summary of the exposure levels of the study drug as well as changes in levels of different types of hemoglobin including fetal and sickle forms of hemoglobin., The study will also check whether other markers connected to sickle cell disease are improving	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026